Concepedia

Publication | Open Access

Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2

20

Citations

24

References

2018

Year

Abstract

Our results revealed that elevated serum miR-4530 levels may sensitize breast cancer to taxane- and anthracycline-based NAC by suppressing RUNX2; therefore, this miRNA has the potential to be a new biomarker for predicting breast cancer chemosensitivity.

References

YearCitations

2015

11.9K

2004

10.8K

2011

2.7K

1998

2.2K

2011

1.9K

1997

1.8K

2008

1.7K

2001

1.3K

2010

332

2005

325

Page 1